SCHEMBL972579

SCHEMBL972579

CC(Cc1cccc(I)c1)C(=O)O

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PLA2G10 O15496 3/20 0.47
PLA2G2A P14555 3/20 0.47
PLA2G1B P04054 1/20 0.47
PLA2G5 P39877 1/20 0.47
PLA2G2C Q5R387 1/20 0.47
PLA2G12B Q9BX93 1/20 0.47
PLA2G12A Q9BZM1 1/20 0.47
PLA2G2F Q9BZM2 1/20 0.47
PLA2G3 Q9NZ20 1/20 0.47
PLA2G2E Q9NZK7 1/20 0.47
PLA2G2D Q9UNK4 1/20 0.47
TBXAS1 P24557 2/20 0.47
CTSB P07858 1/20 0.45
FFAR1 O14842 3/20 0.45
PTGS2 P35354 1/20 0.44
ALB P02768 1/20 0.43
IL2 P60568 1/20 0.43
PPARA Q07869 1/20 0.43
FOLH1 Q04609 1/20 0.41
HPGD P15428 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8257100 0.87 TBXAS1 (0.53) PLA2G10PLA2G2APLA2G1BPLA2G5PLA2G2C
SCHEMBL933328 0.85 CYP1A2 (0.47) PLA2G10PLA2G2APLA2G1BPLA2G5PLA2G2C
SCHEMBL4683900 0.84 LDHA (0.46) CTSBALBIL2FOLH1CYP1A2
SCHEMBL16578231 0.82 SLC7A5 (0.43) CTSBFOLH1CYP2C19
SCHEMBL4683271 0.82 SLC7A5 (0.43) CTSBFOLH1CYP2C19
SCHEMBL3658555 0.81 GRIA2 (0.54) PLA2G10PLA2G2APLA2G1BPLA2G5PLA2G2C
SCHEMBL1410876 0.81 PLA2G10 (0.48) PLA2G10PLA2G2APLA2G1BPLA2G5PLA2G2C
SCHEMBL2498139 0.81 GRIA2 (0.54) PLA2G10PLA2G2APLA2G1BPLA2G5PLA2G2C
SCHEMBL19295495 0.81 CTBP2 (0.49) PLA2G10PLA2G2APLA2G1BPLA2G5PLA2G2C
SCHEMBL2030200 0.81 KDM6B (0.54) CTSBALBIL2FOLH1PTGER4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7875745-B2 {1-[(2S,3S)-2-(2,3-dihydro-1H-inden-2-ylmethyl)-3-(3,5-dimethoxy-4- methylphenyl)-3-hydroxylpropyl]-1H-pyrrol-3-yl}acetic acid; for urinary system disease selected from the group of prostatic hypertrophy, neurogenic bladder dysfunction disease, dysuria, pollakiuria, night urination and urodynia ONO PHARMACEUTICAL CO., LTD. (JP) 2011-01-25 US disclosed
US-20070149595-A1 Compounds having lysophosphatidic acid receptor antagonism and uses thereof ONO PHARMACEUTICAL CO., LTD. (JP) 2007-06-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070149595-A1 Compounds having lysophosphatidic acid receptor antagonism and uses thereof LPAR2, LPAR1, LPAR5 PLA2G10 34/4885PLA2G2A 17/4885PLA2G1B 19/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.